Zuclomifene

From Wikipedia, the free encyclopedia
  (Redirected from (Z)-clomiphene)
Jump to: navigation, search
Zuclomifene
Zuclomifene.png
Clinical data
Synonyms Zuclomiphene; trans-Clomifene; Transclomiphene; (Z)-Clomifene; ICI-46476; RMI-16312; Zuclomifene citrate; Zuclomiphene citrate
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C26H28ClNO
Molar mass 405.966 g/mol
3D model (JSmol)

Zuclomifene (INN), or zuclomiphene (USAN), is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was never marketed.[1][2][3][4] It is one of the two stereoisomers of clomifene, which itself is a non-racemic mixture of 38% zuclomifene and 62% enclomifene.[4] Zuclomifene is the (Z)-enantiomer of clomifene, while enclomifene is the (E)-enantiomer.[1][2] Whereas zuclomifene is described as mildly estrogenic, enclomifene is described as antiestrogenic.[4][5] In accordance, unlike enclomifene, zuclomifene is antigonadotropic due to activation of the estrogen receptor and is able to reduce testosterone levels in men to near-castrate levels.[4] It is also about 5 times more potent than enclomifene in inducing ovulation.[5]

References[edit]

  1. ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 298–. ISBN 978-1-4757-2085-3. 
  2. ^ a b I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 79–. ISBN 978-0-7514-0499-9. 
  3. ^ http://webcache.googleusercontent.com/search?q=cache:rTob_FmpvpUJ:adisinsight.springer.com/drugs/800019625+&cd=1&hl=en&ct=clnk&gl=us
  4. ^ a b c d Hill S, Arutchelvam V, Quinton R (2009). "Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men" (PDF). IDrugs. 12 (2): 109–19. PMID 19204885. 
  5. ^ a b Janos Fischer; C. Robin Ganellin; David P. Rotella (15 October 2012). Analogue-based Drug Discovery III. John Wiley & Sons. pp. 5–. ISBN 978-3-527-65110-8.